Table Info

Table 1.

Baseline demographic and clinical characteristics

Characteristic	Memantine	Sodium valproate	P*
Female sex—no (%)	13 (81.25%)	13 (76.47%)	0.54
Male sex—no (%)	3 (18.75%)	4 (23.52%)	0.54
Age	31.18 ± 10.94^§	31.58 ± 7.51^§	0.91
A family history of migraine (%)	10 (62.5%)	9 (52.94%)	0.82
Clinical characteristics Photophobia—no (%)	14 (87.50%)	16 (94.12%)	0.48
Phonophobia—no (%)	16 (100%)	10 (58.82%)	0.60
Nausea—no (%)	14 (87.5%)	17 (100%)	0.23
Disability activities of daily living (%)	15 (93.75%)	16 (94.12%)	0.74
Migraine without aura (%)	13 (81.25%)	13 (76.47%)	0.54
Migraine with aura (%)	3 (18.75%)	4 (23.52%)	0.54

Fisher’s exact test; ^§ plus-minus values are means ± standard deviation (SD)

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/100442_sup_1.pdf.

Declarations

Acknowledgments

Thanks are due to Torrent Pharmaceuticals, Mexico for providing both memantine and valproate for this study.

Author contributions

DVG: Conceptualization, Resources, Data curation, Writing—original draft, Writing—review & editing. IRL: Conceptualization, Writing—review & editing. AON: Investigation, Writing—review & editing. FRR: Resources. HGHR and JMSM: Formal analysis. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The protocol study was approved by the Research and Ethics committees of Hospital Central (no. 74-19). It was also registered in the National Institutes of Health Clinical Trials of the United States (registration NCT04698525 for clinical trials) and complied with the Declaration of Helsinki and its later amendments.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Informed consent to publication was obtained from relevant participants.

Availability of data and materials

The datasets for this study can be found in the Clinical Trials of the National Institutes of Health of the United States (https://clinicaltrials.gov/ct2/results?pg=1&load=cart&id=NCT04698525).

Funding

Not applicable.

Copyright

References

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–858. [DOI] [PubMed] [PMC]

Bille B. A 40-year follow-up of school children with migraine. Cephalalgia. 1997;17:488–91. [DOI] [PubMed]

Schwedt TJ. Preventive therapy of migraine. Continuum (Minneap Minn). 2018;24:1052–65. [DOI] [PubMed] [PMC]

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45. [DOI] [PubMed] [PMC]

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–88. [DOI] [PubMed]

Nguyen JL, Munshi K, Peasah SK, Swart ECS, Kohli M, Henderson R, et al. Trends in utilization and costs of migraine medications, 2017–2020. J Headache Pain. 2022;23:111. [DOI] [PubMed] [PMC]

Dodick DW. Migraine. Lancet. 2018;391:1315–30. [DOI] [PubMed]

Chan K, MaassenVanDenBrink A. Glutamate receptor antagonists in the management of migraine. Drugs. 2014;74:1165–76. [DOI] [PubMed]

Ferrari A, Rustichelli C, Baraldi C. Glutamate receptor antagonists with the potential for migraine treatment. Expert Opin Investig Drugs. 2017;26:1321–30. [DOI] [PubMed]

10.

Charles A, Flippen C, Romero Reyes M, Brennan KC. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain. 2007;8:248–50. [DOI] [PubMed] [PMC]

11.

Noruzzadeh R, Modabbernia A, Aghamollaii V, Ghaffarpour M, Harirchian MH, Salahi S, et al. Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled study. Headache. 2016;56:95–103. [DOI] [PubMed]

12.

Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211. [DOI] [PubMed]

13.

Wells RE, Turner DP, Lee M, Bishop L, Strauss L. Managing migraine during pregnancy and lactation. Curr Neurol Neurosci Rep. 2016;16:40. [DOI] [PubMed]

14.

Tonini MC. Gender differences in migraine. Neurol Sci. 2018;39:77–8. [DOI] [PubMed]